Key result
Amiodarone administration in a 25-year-old male with supraventricular tachycardia and latent AV nodal disease caused extreme PR interval prolongation exceeding 400 ms, resulting in pseudo-pacemaker syndrome.
Why the study?
Amiodarone's substantial impact on atrioventricular nodal conduction can obscure or exacerbate underlying delays, resulting in rare conditions such as pseudo-pacemaker syndrome.
Case Report (n=1)
No
Amiodarone can exacerbate latent AV nodal disease in young adults, leading to extreme PR prolongation and pseudo-pacemaker syndrome, underscoring the need for cautious use and monitoring.
Answers are grounded in this paper and cite their sources.
May prompt closer PR monitoring after amiodarone in patients with possible latent AV nodal disease; hypothesis-generating case report requiring confirmation.
Amiodarone is a potent antiarrhythmic that is used to treat supraventricular tachycardia (SVT). However, its substantial impact on atrioventricular (AV) nodal conduction can obscure or exacerbate underlying delays, resulting in rare conditions such as pseudo-pacemaker syndrome (PPMS). This syndrome is the result of an extreme prolongation of the PR interval, which results in AV dyssynchrony and hemodynamic compromise in the absence of an implanted device. A 25-year-old male presented with SVT, which was further complicated by hypokalemia. The case revealed a pre-existing AV nodal conduction delay. Therefore, we present the case. The patient transitioned to sinus rhythm after receiving amiodarone; however, they experienced a persistent and severe PR interval prolongation that exceeded 400 ms. The symptoms of vertigo and palpitations, which were consistent with PPMS, were induced by this severe conduction block and persisted for more than ten days, a reflection of the long half-life of amiodarone. This case concludes that amiodarone can dangerously exacerbate latent AV nodal disease in young adults, underscoring the necessity of recognizing PPMS as a clinical consequence of iatrogenic PR prolongation and emphasizing the need for cautious use and monitoring of antiarrhythmic drugs in patients with any evidence of conduction abnormalities.
No takes yet. Share an insight, caveat, or question.
Mamasta et al. (2025) conducted a case report in Supraventricular tachycardia and pseudo-pacemaker syndrome (n=1). Amiodarone was evaluated on PR interval prolongation. Amiodarone administration in a 25-year-old male with supraventricular tachycardia and latent AV nodal disease caused extreme PR interval prolongation exceeding 400 ms, resulting in pseudo-pacemaker syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: